OpGen (NASDAQ:OPGN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Stock Up 4.0 %

Shares of OPGN opened at $2.10 on Friday. OpGen has a 1 year low of $1.75 and a 1 year high of $38.40. The company has a 50 day simple moving average of $2.35 and a two-hundred day simple moving average of $3.69.

OpGen (NASDAQ:OPGN) last announced its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) EPS for the quarter. OpGen had a negative net margin of 1,140.36% and a negative return on equity of 1,827.76%. The firm had revenue of $0.03 million for the quarter.

Hedge Funds Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp acquired a new position in shares of OpGen, Inc. (NASDAQ:OPGN) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned 2.63% of OpGen as of its most recent SEC filing. 2.68% of the stock is currently owned by institutional investors and hedge funds.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.